FDA panel to review risk reclassification of electroshock systems

01/24/2011 | New York Times (tiered subscription model), The

An FDA panel will hold a meeting beginning Thursday to discuss whether to reclassify electroshock devices, which are used to treat major depression, from the high-risk category to medium-risk. The FDA review comes amid calls from specialists and psychiatric groups, including the American Psychiatric Association, for the downgraded device designation.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD